Vivos Therapeutics, Inc.2025财年第三财季实现净利润-5.40百万美元，同比减少106.11%

市场透视11-24

11月24日，Vivos Therapeutics, Inc.（VVOS.US）公布财报，公告显示公司2025财年第三财季净利润为-5.40百万美元，同比减少106.11%；其中营业收入为6.78百万美元，同比增加75.65%，每股基本收益为-0.49美元。从资产负债表来看，Vivos Therapeutics, Inc.（VVOS.US）总负债23.11百万美元，其中短期债务1.13百万美元，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2585438162?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-11-24 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2585438162","market":"us","top_or_hot":-1,"title":"Vivos Therapeutics, Inc.2025财年第三财季实现净利润-5.40百万美元，同比减少106.11%","media":"市场透视","content":"<div>\n<p>11月24日，Vivos Therapeutics, Inc.（VVOS.US）公布财报，公告显示公司2025财年第三财季净利润为-5.40百万美元，同比减少106.11%；其中营业收入为6.78百万美元，同比增加75.65%，每股基本收益为-0.49美元。从资产负债表来看，Vivos Therapeutics, Inc.（VVOS.US）总负债23.11百万美元，其中短期债务1.13百万美元，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124000109a4b53d0c&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vivos Therapeutics, Inc.2025财年第三财季实现净利润-5.40百万美元，同比减少106.11%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVivos Therapeutics, Inc.2025财年第三财季实现净利润-5.40百万美元，同比减少106.11%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-24 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124000109a4b53d0c&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>11月24日，Vivos Therapeutics, Inc.（VVOS.US）公布财报，公告显示公司2025财年第三财季净利润为-5.40百万美元，同比减少106.11%；其中营业收入为6.78百万美元，同比增加75.65%，每股基本收益为-0.49美元。从资产负债表来看，Vivos Therapeutics, Inc.（VVOS.US）总负债23.11百万美元，其中短期债务1.13百万美元，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124000109a4b53d0c&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124000109a4b53d0c&s=b","article_id":"2585438162","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124000109a4b53d0c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2585438162","pubTimestamp":1763913654,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"11月24日，Vivos Therapeutics, Inc.公布财报，公告显示公司2025财年第三财季净利润为-5.40百万美元，同比减少106.11%；其中营业收入为6.78百万美元，同比增加75.65%，每股基本收益为-0.49美元。从资产负债表来看，Vivos Therapeutics, Inc.总负债23.11百万美元，其中短期债务1.13百万美元，资产负债比为1.11，流动比率为0.78。机构评级：截至2025年11月24日，当前有3家机构对Vivos Therapeutics, Inc.目标价做出预测，其中目标均价为5.83美元，其中最低目标价为4.00美元，最高目标价为7.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"LENZ":"Therapeutics","VVOS":"Vivos Therapeutics"},"translate_title":"Vivos Therapeutics, Inc. achieved net profit of-US $5.40 million in the third fiscal quarter of fiscal year 2025, a year-on-year decrease of 106.11%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VVOS":1.5,"LENZ":1.5},"content_text":"11月24日，Vivos Therapeutics, Inc.（VVOS.US）公布财报，公告显示公司2025财年第三财季净利润为-5.40百万美元，同比减少106.11%；其中营业收入为6.78百万美元，同比增加75.65%，每股基本收益为-0.49美元。从资产负债表来看，Vivos Therapeutics, Inc.（VVOS.US）总负债23.11百万美元，其中短期债务1.13百万美元，资产负债比为1.11，流动比率为0.78。机构评级：截至2025年11月24日，当前有3家机构对Vivos Therapeutics, Inc.目标价做出预测，其中目标均价为5.83美元，其中最低目标价为4.00美元，最高目标价为7.00美元。公司简介：Vivos Therapeutics Inc是一家医疗技术公司。它专注于开发和商业化为睡眠呼吸障碍(SDB)患者，包括轻度至中度阻塞性睡眠呼吸暂停综合征(OSA)的患者，提供非手术、无创伤、非药物和低成本的技术。 该公司为轻度至中度阻塞性睡眠呼吸暂停综合征(OSA)的患者提供治疗，涉及定制口腔矫治器和称为Vivos系统的方案。Vivos系统是一种治疗方案，通常结合使用定制口腔矫治器和专有临床治疗方法，该治疗方法由该公司开发并由经过专门培训的牙医与该公司的医疗团队合作开具处方。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2585438162","isCrawlerRequest":true}